AU2734197A - Correlating polymorphic forms with multiple phenotypes - Google Patents

Correlating polymorphic forms with multiple phenotypes

Info

Publication number
AU2734197A
AU2734197A AU27341/97A AU2734197A AU2734197A AU 2734197 A AU2734197 A AU 2734197A AU 27341/97 A AU27341/97 A AU 27341/97A AU 2734197 A AU2734197 A AU 2734197A AU 2734197 A AU2734197 A AU 2734197A
Authority
AU
Australia
Prior art keywords
correlating
polymorphic forms
multiple phenotypes
phenotypes
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27341/97A
Other languages
English (en)
Inventor
Stephen J. Peroutka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SPECTRA BIOMEDICAL Inc
Original Assignee
SPECTRA BIOMEDICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SPECTRA BIOMEDICAL Inc filed Critical SPECTRA BIOMEDICAL Inc
Publication of AU2734197A publication Critical patent/AU2734197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
AU27341/97A 1996-04-19 1997-04-18 Correlating polymorphic forms with multiple phenotypes Abandoned AU2734197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63651796A 1996-04-19 1996-04-19
US08636517 1996-04-19
PCT/US1997/006457 WO1997040462A2 (en) 1996-04-19 1997-04-18 Correlating polymorphic forms with multiple phenotypes

Publications (1)

Publication Number Publication Date
AU2734197A true AU2734197A (en) 1997-11-12

Family

ID=24552242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27341/97A Abandoned AU2734197A (en) 1996-04-19 1997-04-18 Correlating polymorphic forms with multiple phenotypes

Country Status (4)

Country Link
EP (1) EP0897567A2 (de)
JP (1) JP2000508912A (de)
AU (1) AU2734197A (de)
WO (1) WO1997040462A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100963A2 (de) * 1998-07-25 2001-05-23 AstraZeneca AB Polymorphismen des humanen ccr-2 gens
JP2002526090A (ja) * 1998-09-19 2002-08-20 アストラゼネカ・アクチエボラーグ インテグリンリガンド仲介疾患の診断および処置に適当なヒトのベータ１インテグリンサブユニット遺伝子における多型性
EP1112381A1 (de) * 1998-09-19 2001-07-04 AstraZeneca AB Polymorphismen im gen für die alpha4 untereinheit des humanen integrins, geeignet zur diagnostik und behandlung von integrin-ligand vermittelten erkrankungen
GB9820338D0 (en) * 1998-09-19 1998-11-11 Zeneca Ltd Chemical compounds
EP1233365A3 (de) * 1999-06-25 2004-11-17 Genaissance Pharmaceuticals, Inc. Verfahren zur herstellung und verwendung von Haplotype Daten
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
WO2001027857A2 (en) 1999-10-13 2001-04-19 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
GB0000992D0 (en) * 2000-01-18 2000-03-08 Astrazeneca Uk Ltd Methods
GB0000995D0 (en) * 2000-01-18 2000-03-08 Zeneca Ltd Methods
GB0001005D0 (en) * 2000-01-18 2000-03-08 Zeneca Ltd Methods
GB0002366D0 (en) * 2000-02-03 2000-03-22 Astrazeneca Uk Ltd Diagnostic method
US20020076702A1 (en) * 2000-02-17 2002-06-20 Rakesh Anand Methods
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
WO2002006523A2 (en) 2000-07-14 2002-01-24 F. Hoffmann-La Roche Ag Method for detecting pre-disposition to hepatotoxicity
GB0021667D0 (en) * 2000-09-04 2000-10-18 Glaxo Group Ltd Genetic study
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
EP1741722A3 (de) * 2000-10-21 2007-03-14 AstraZeneca AB Polymorphismen des menschlichen P2X7 Gens
CA2387277C (en) * 2001-05-25 2015-03-03 Hitachi, Ltd. Information processing system using nucleotide sequence-related information
JP2003067389A (ja) * 2001-06-29 2003-03-07 Dainakomu:Kk 遺伝子多型関連解析方法およびそのプログラム
FI20012593A0 (fi) * 2001-12-28 2001-12-28 Pertti Laehteenmaeki Menetelmä ja järjestelmä ravitsemustietopalvelun järjestämiseksi
FI20021031A (fi) * 2001-12-28 2003-06-29 Pertti Laehteenmaeki Ravintoautomaatti
DE10207971A1 (de) * 2002-02-25 2003-09-11 Norbert Dahmen Verfahren zur Identifizierung Nebenwirkungs-relevanter Markerprofile
AUPS115502A0 (en) * 2002-03-18 2002-04-18 Diatech Pty Ltd Assessing data sets
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
EP2500440B1 (de) 2002-12-20 2015-12-16 Celera Corporation Mit Myokardinfarkt assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
AU2004265494A1 (en) * 2003-08-14 2005-02-24 Mars, Incorporated IgA allelic variants
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
CA3048093A1 (en) 2003-11-26 2005-06-23 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
AU2005230936B2 (en) 2004-03-26 2010-08-05 Agena Bioscience, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
EP1745154B1 (de) 2004-05-07 2012-08-01 Celera Corporation Genetische polymorphismen assoziiert mit leberfibrose, verfahren zur detektion und verwendung davon
EP1812473A4 (de) 2004-11-16 2009-12-23 Univ Boston Funktionen des dualen endothelin-1/angiotensin-ii-rezeptors (dear) bei hypertonie und angiogenese
EP1856296A2 (de) 2005-03-11 2007-11-21 Applera Corporation Genetische polymorphismen in zusammenhang mit koronarer herzerkrankung, detektionsverfahren und verwendungen
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7695911B2 (en) 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
CA2915679C (en) 2006-10-20 2017-12-12 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
EP2733222A1 (de) 2008-07-09 2014-05-21 Celera Corporation Mit kardiovaskulären Krankheiten assoziierte, genetische Polymorphismen, Verfahren zum Nachweis und Verwendungen davon
ES2589377T3 (es) 2009-08-21 2016-11-14 Novartis Ag Lapatinib para el tratamiento del cáncer
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
CN103384887B (zh) 2010-05-25 2017-01-18 加利福尼亚大学董事会 Bambam：高通量测序数据的平行比较分析
GB201008727D0 (en) 2010-05-25 2010-07-07 Glaxo Group Ltd Biomarkers
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
BR112014019034A8 (pt) 2012-01-31 2017-07-11 Smithkline Beecham Cork Ltd Método para tratamento de câncer
KR102456013B1 (ko) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지

Also Published As

Publication number Publication date
EP0897567A2 (de) 1999-02-24
WO1997040462A2 (en) 1997-10-30
WO1997040462A3 (en) 1998-03-05
JP2000508912A (ja) 2000-07-18

Similar Documents

Publication Publication Date Title
AU2734197A (en) Correlating polymorphic forms with multiple phenotypes
AU2841197A (en) Icing set
AU2845197A (en) Cycloalkano-pyridines
AU4945197A (en) Aminothiophenecarboxamides
AU3102797A (en) Cell adhesion inhibiting compounds
AU4013397A (en) Arylalkanoylpyridazines
AU4176997A (en) 3-alkyl-3-phenyl-piperidines
AU2684197A (en) Handleset
AU4218597A (en) Superseat
AU8904098A (en) Protective coverings
AU4460497A (en) Mycosis vaccines
AU1761797A (en) Corrosion preventing covering
AU3130597A (en) Tristetraprolin
AU1900097A (en) Cremators
AU2237197A (en) Fishing-lure
AU4332497A (en) Endo-beta-galactosidase
AU2895097A (en) New thiazolopyridines
AU1597197A (en) Thienoquinolines
AU1643797A (en) Repeater-system
AU3155797A (en) Constructional element
AU4110897A (en) Horse-nail
AU5127498A (en) Constructional element
AU4716197A (en) Transinduction
AU4942997A (en) Halogenalkoximinoacetamide
AU1445197A (en) 3-methylimidazopyridines